Announced details
Patients with acute spinal cord injury
jRCT2031260281, NCT07722962 (expiration date undisclosed)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634.
Shingu Hikosuke (新宮彦助), “Prevention of Spinal Cord Injury,” Journal of the Japanese Paraplegia Medical Society 13:48-49, 2000
Sakai Hiroaki (坂井宏旭), “Epidemiological Survey,” Comprehensive Rehabilitation 36:969-972, 2008
| Item | Details |
|---|---|
| Names of Products / Services Covered | Oremepermin alfa, HGF (hepatocyte growth factor) |
| Launch date | Final preparations are underway to begin patient enrollment (start date undisclosed) |
| Applicable area | Patients with acute spinal cord injury |
| Registration number and expiry date | jRCT2031260281, NCT07722962 (expiration date undisclosed) |
| Source | Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634., Shingu Hikosuke (新宮彦助), “Prevention of Spinal Cord Injury,” Journal of the Japanese Paraplegia Medical Society 13:48-49, 2000, Sakai Hiroaki (坂井宏旭), “Epidemiological Survey,” Comprehensive Rehabilitation 36:969-972, 2008 |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To publish an overview of the trial and advance development with the aim of ensuring a smooth launch and enrolling patients at an early stage.